Ticagrelor, a drug commonly used as a platelet aggregation inhibitor, received approval from U.S. Food and Drug Administration (USFDA) in July 2011 and in the European Union by the European Commission in December, 2010. Ticagrelor is used for the prevention of thrombotic events such as stroke or heart attack in people with acute coronary syndrome or myocardial infarction with ST wave elevation.
Rising prevalence of cardiovascular diseases is attributed to rising geriatric population and changing lifestyles. According to World Health Organization (WHO), around 17.9 million people every year die due to cardiovascular diseases (CVDs), which is about 31% of all global deaths. This is expected to positively impact growth of the ticagrelor market over the next decade.
Furthermore, in September 2016, WHO launched the Global Hearts Initiative through which WHO is supporting governments around the world to improve efforts on CVD prevention and control. Thus, increasing number of non-government and government initiatives, in order to aid in prevention of CVD is expected to help in propelling growth of the ticagrelor market over the forecast period.
- This report provides in-depth analysis of the ticagrelor market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global ticagrelor market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, ANHUI HAIKANG PHARMACEUTICAL CO., LTD., Avra Laboratories Pvt Ltd., and Sun Pharmaceutical Industries Ltd
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global ticagrelor market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for ticagrelor market, research and consulting firms, new entrants, and financial analysts
-
-
- Acute Coronary Syndrome
- Ischemic Stroke
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- C.H. Boehringer Sohn AG & Ko. KG
- Pfizer Inc.
- Eli Lilly and Company
- AstraZeneca plc
- Natco Pharma Limited
- Anhui Haikang Pharmaceutical Co., Ltd.
- Avra Laboratories Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
